In 2016 Lindsey became the first American woman to receive a uterus transplant.
Sadly she later loss the womb due to complications.
Part 1
of this article is essentially my lay-persons view of the progress that
medical science is making towards enabling male-to-female transsexuals
to bear children. It is largely based on news reports (often
overly optimistic, e.g. see the article to the right) as very few
relevant medical papers have been published, and these are difficult
and/or expensive for a non-medical professional such as myself to obtain
- either in hard copy or from a subscription site such as
PubMed and the Web of Science .
However, in
December 2018 I obtained from
The British Journal of Obstetrics & Gynaecology (BJOG) the article "Uterine
transplantation in transgender women ". It provides an
extremely informative synopses of the current situation, and the medical
challenges that still need to be overcome before the first transwomen become pregnant. It's been
published as an open access article under the terms of the Creative
Commons Attribution which permits use, distribution and reproduction in
any medium. I have therefore saved a copy of the full article in
PDF format
here -
before it disappears to the subscription-only sites.
A very
slightly edited version is provided below:
Introduction
Gender dysphoria, defined as the persistent
discomfort with one's gender identity or biological sex, affects between
0.5 and 1.4% of adult males. Treatment aims at congruence, to allow
those who experience it to find comfort within their gendered self,
which optimises psychological wellbeing and self‐fulfilment. Although
many experiencing gender dysphoria require partial treatment or social
transition, others only find comfort following surgical intervention to
change their external genitalia and sexual characteristics.
Traditionally, infertility has been an unfortunate consequence of the
realignment of a transgender person's body with their gender identity.
Following a successful clinical trial
investigating uterine transplantation (UTx) in Sweden, resulting in
eight live births so far, UTx appears to be a viable therapeutic option
for women with absolute uterine factor infertility (AUFI). More than 42
UTx procedures have now been performed globally, and at least 12 live
births have been reported. Following the establishment of the
International Society of Uterine Transplantation (ISUTx), and the
formation of research teams globally, it is anticipated that UTx will
make the transition from research to clinical care in the future.
Following these developments, speculation has escalated regarding the
possibility of performing UTx in male to female (M2F) transgender women,
which would enable them to gestate and give birth to their own children.
Ethically, the consideration of performing UTx
in transgender women is primarily motivated by the considerations of
justice and equality. Like all women, psychological harm may arise
secondary to a mismatch between reproductive capacity and aspiration.
Transgender women have AUFI, and therefore they cannot experience
gestation, which may play an integral role in the expression and
consolidation of a female identity, and is considered by many to
constitute a transformative experience.6 Legally, under the Equality Act
(2010) transgender people are afforded explicit protection from both
direct and indirect forms of discrimination through the characterisation
of ‘gender reassignment’ as a protected characteristic. As such, M2F
transgender women cannot be subjected to discrimination on the basis of
this characteristic. Subsequently, if UTx becomes an established
treatment option for women with AUFI, UK and EU legislation would make
it legally impermissible to refuse to perform UTx in transgender women
solely because of their gender identity. Performing UTx in this
population, however, raises a number of anatomical, physiological,
fertility, and obstetric considerations. The aim of this manuscript is
to discuss these factors and provide an initial framework for assessing
the feasibility of UTx in M2F transgender women.
Anatomical considerations
Uterine transplantation entails the
transplantation of the uterus, including the cervix, a cuff of vagina,
the surrounding ligamentous and connective tissues, as well as the major
blood vessels to the level of the internal iliac vessels. The uterus is
then placed orthotopically in the pelvis of the recipient, where it is
structurally supported using the uterosacral, round and broad ligaments
laterally, the bladder peritoneum anteriorly, and the vagina and
paravaginal tissues inferiorly.
V ascular anastomosis
Most UTx procedures performed to date have
achieved revascularisation through bilateral internal iliac artery to
external iliac end‐to‐side anastomoses. To determine the plausibility of
retrieving a graft from a woman, with subsequent implantation into a
natal male pelvis, the intersex differences in pelvic vascular anatomy
require consideration. Fătu et al.
assessed the
morphometry of the internal iliac arteries between sexes, and concluded
there was no difference in internal iliac artery length, with a mean
length of 49 mm. However, the calibre of the vessels was noted to be 1.6
mm wider in females than in males (6.2 versus 7.8 mm). Although a
significant funnelling effect could predispose to thrombosis, this
difference could be negated by anastomosing further proximally, where
the vessels are similarly sized. With regard to the external iliac
arteries, data from lower limb angioplasties show there is no
significant difference in external iliac artery calibre between sexes.
V aginal anastomosis
In all UTx
cases performed to date, the recipient's vagina has been anastomosed to
a vaginal cuff, of varying length, which is retrieved as part of the
graft. This restores reproductive anatomy and allows physiological
excretion of discharge and menstruation, but also allows direct
visualisation of the cervix and access to take biopsies, which is the
only reliable way to detect rejection following UTx.9 In the M2F
transgender model, it would therefore only be possible following gender
reassignment surgery (GRS), which traditionally includes orchidectomy,
penectomy, clitoroplasty, and labiaplasty, with the subsequent creation
of a neovagina. The inverted penile skin flap is the standard technique
for neovagina creation, to line a newly created
space between the bladder/prostate and the rectum. However intestine, or
pelvic peritoneum,12 have also be utilised, particularly in cases with
penoscrotal hypoplasia, which can be an iatrogenic consequence of
feminising hormones. However, the absence of a physiologically
functioning vaginal mucosa may be problematic. The vagina is lined by
multiple layers of stratified squamous epithelium, the top layer of
which removes adherent micro‐organisms by desquamation into the vaginal
lumen. Vaginal epithelium also facilitates the
recognition of pathogens and stimulates production of antimicrobial
peptides and pro‐inflammatory cytokines. These protective mechanisms
contribute to the creation of a commensal microflora, predominantly
consisting of lactobacilli, which provides an optimal physiological
environment to prevent infection and maintain pregnancy. In M2F
transgender women, the pH in penile skin‐lined neovaginas is elevated,
owing to an inability to support the growth of acidic lactobacilli, with
colonisation of bacteria from skin or intestinal microfloras
instead. Following M2F transgender UTx, the presence of a skin or
intestinal neovagina, in the context of immunosuppression, may increase
susceptibility to recurrent neovaginal infections and create a hostile
environment that may be incapable of sustaining pregnancy. This was
exemplified in the UTx case performed in Turkey in a recipient with an
intestinal neovagina. Despite multiple embryo transfers and at least six
early pregnancy miscarriages, she has yet to achieve a live
birth.17Moreover, the only woman in the Swedish series to have not yet
given birth following successful UTx, despite suffering at least five
miscarriages, has a skin neovagina. Although it appears the absence of a
physiologically functioning vagina is detrimental, albeit to a currently
unquantified extent, small numbers of live births have been reported in
women with skin neovaginas, including two following UTx in the Swedish
series, highlighting that successful pregnancy is
possible.
To overcome this anatomical hindrance in M2F
transgender women, a utero‐vaginal transplant could be performed,
utilising as much donor vagina as possible, en‐bloc with the uterus
(Figure 1). This would be achievable using a similar technique to that
employed at radical hysterectomy, with preservation of the vaginal
branches of the uterine vessels. This would necessitate retrieval from
deceased donors, excluding female living donors. An alternative donor
pool may be female to male (F2M) transgender men undergoing hysterectomy
and vaginectomy, although the increased radicality of the hysterectomy
may not be acceptable. However, recent evolution of the surgical
technique, following cases in China and Dallas has potentially
significantly reduced donor risk. The modified technique utilises venous
drainage of the graft via the ovarian or utero‐ovarian veins, as opposed
to the unpredictable and tortuous uterine venous plexus which leads to
the internal iliac veins. This negates the need for the complex and
time‐consuming ureteric dissection away from the uterine veins, reducing
surgical risk. Moreover, it reduces operative times from 12 hours to 4–5
hours, which in turn decreases potential venous thromboembolism (VTE)
risk. This dissection also favours minimally invasive retrieval
techniques, which should enhance recovery and reduce potential morbidity
further. As most F2M transgender men will also undergo bilateral
oophorectomy, whereas the ovaries it would not be transplanted, it would
allow the retrieval of elongated ovarian vascular pedicles to facilitate
the implantation.
Figure 1
:
Proposed utero‐vaginal retrieval operation with
incision markings (left) and the utero‐vaginal transplant graft
following retrieval, including vascular pedicles (right).
The graft for implantation, using deceased
donors, is displayed in Figure 1. This would be anastomosed to the
recipient's neovagina as shown in Figure 2. Although prostatectomy is
not routinely undertaken in GRS, the oestrogenised environment in
transgender women causes prostatic atrophy, which should not cause a
structural hindrance in UTx.
Figure 2
:
Male to female transgender anatomy following
utero‐vaginal transplantation demonstrating vascular and vaginal
anastomoses (left), and ligamentous support following implantation
(right).
Ligamentous support
The ligamentous and soft tissue support is
provided anteriorly by approximating donor and recipient bladder
peritoneum. This technique is directly transferable to the M2F
transgender model. Postero‐laterally, the broad and uterosacral
ligaments from the donor are connected to the pelvic side wall and
uterosacral remnants, respectively, in the recipient. Although M2F
transgender women do not have uterosacral remnants, this could be
overcome by a more radical ligamentous retrieval, with subsequent
anastomosis to the recipient paraneovaginal region (Figure 2).
H ormonal
factors
Exogenous estrogen optimises the development of
female secondary sexual characteristics, whereas anti‐androgens, such as
spironolactone or finasteride, minimise male features. Progestogen is
not routinely administered, as its role in feminisation remains unclear.
However, considering that unopposed estrogen is a significant
risk factor for endometrial hyperplasia and endometrial carcinoma in
post‐menopausal women, progestogen supplementation would become
essential in transgender women following UTx.
Continuous hormone replacement therapy (HRT) is
the usual regimen prescribed in M2F transgender women, but sequential
HRT would be more appropriate following UTx in transgender women. Not
only is withdrawal bleeding an important sign of graft function, but it
is intrinsically part of being female and therefore contributes to
gender identity, which may have psychological benefits.
Graft thrombosis is one of the most common
serious complications following organ transplantation. Although oral
estrogen was previously implicated in an increased VTE risk in M2F
transgender women, this was later attributed to the use of
ethinylestradiol, a particularly thrombogenic estrogen that is no longer
in routine use. A subsequent study on 2236 M2F transgender individuals
reaffirmed this, with no additional risk of VTE seen in those receiving
different hormone therapy.
Fertility considerations
Fertility preservation should be discussed in
all M2F cases prior to the commencement of hormone therapy or
contemplation of GRS. M2F transgender women can preserve their fertility
prior to transition using sperm cryopreservation, with subsequent in
vitro fertilisation (IVF) or intrauterine insemination (IUI) in a female
partner or surrogate.
Following UTx, embryo transfer should not be
attempted until at least 6 months postoperatively, to allow healing and
stabilisation of immunosuppression. Achieving pregnancy may be feasible
utilising hormone regimens that have been used with success in women
with premature ovarian insufficiency or following physiological
menopause. Following the withdrawal bleed on sequential combined HRT,
estrogen supplementation should be commenced to stimulate the
endometrium. Once >7 mm in thickness, progesterone should be
supplemented to maintain the endometrial lining for implantation. A
single embryo can then be transferred into the uterus. Multiple embryo
transfers should be avoided owing to the additional risks associated
with multiple gestations. All women should have previously undergone
orchidectomy, with resultant low testosterone levels. However, if
anti‐androgens such as finasteride or spironolactone are being taken,
these should also be stopped in advance of fertility treatment, owing to
their teratogenic potential.
Obstetric considerations
Male pelvises differ from their female
counterparts, to an extent that they can be used to determine gender at
autopsy. This dimorphism has evolved as a consequence to sex‐specific
selection pressures. Natal males need a pelvis suitable for bipedal
locomotion, whereas the female pelvis must also accommodate a fetus
during pregnancy and be adequately capacious for childbirth. Although
most skeletal measurements are larger in males than females, the true
pelvis of the female has evolved to become larger and broader. This
dimorphism is most marked at the antero‐posterior diameter of the pelvic
inlet, the transverse diameter of the midplane between the ischial
spines, and the transverse diameter of the pelvic outlet. Moreover,
whereas the pelvic inlet is oval‐shaped in females, it is heart‐shaped
in males. These intersex differences in pelvic morphology would
predispose M2F females after UTx to cephalopelvic disproportion should
labour be attempted. However, as the requisite mode of delivery in women
following UTx is caesarean section, owing to concerns regarding the
mechanical strain of labour, this should also be the case in M2F
transgender women.
Sexual dimorphism arises predominantly due to
the outcome of gender‐determined autosomal genes, which are regulated by
sex‐specific hormones and influenced by hormone receptor
sensitivity. This dimorphism has been demonstrated in the pelvis, where
despite similar growth patterns throughout childhood, it is not until
puberty when the growth trajectory increases in females, and not until
the late twenties when the pelvis attains the most favourable obstetric
dimensions. As such, if M2F transgender women undergo hormone therapy at
a young enough age, they may develop similar pelvic morphology to natal
females. Although there is no evidence in the context of M2F transgender
women, the opposite effect has been demonstrated in female to male (F2M)
transgender men, where a biometric analysis of pelvic characteristics
after the onset of hormone therapy revealed evidence of
‘masculinisation’.
Conclusion
Despite a number of anatomical, hormonal,
fertility, and obstetric considerations that require consideration,
there is no overwhelming clinical argument against performing UTx as
part of GRS. However, the increased radicality associated with the
retrieval operation, including a longer vaginal cuff and more extensive
ligamentous dissection, potentially necessitates the use of deceased
donors. Alternatively, F2M transgender men may offer an alternative
donor pool should they accept the increased risk compared with standard
hysterectomy. Prior to undertaking UTx in transgender women, further
research should be undertaken including cadaveric retrieval and
implantations to assess the feasibility of the anatomical considerations
discussed herein. Furthermore, it is recommended that animal studies are
revisited to identify potential unknown risks and determine whether
genetic males can successfully conceive and maintain pregnancy.
The reproductive aspirations of M2F transgender
women deserve equal consideration to those assigned female at birth and,
subject to feasibility being shown in the suggested areas of research,
it may be legally and ethically impermissible not to consider performing
UTx in this population.
Funding
This work was supported by the Wellcome Trust
[097897/Z/11/Z].
Acknowledgements
The authors would like to thank Dee McLean for
the artwork in Figures 1 and 2.